Breaking News Instant updates and real-time market news.

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/19/18
11/19
04:55
11/19/18
04:55

American College of Allergy, Asthma & Immunology to hold a meeting

2018 ACAAI Meeting will be held in Seattle, WA on November 15-19.

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

NVS Novartis
$87.74

0.52 (0.60%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
11/16/18
GSCO
11/16/18
UPGRADE
GSCO
Conviction Buy
Novartis upgraded to Conviction Buy from Neutral at Goldman Sachs
10/29/18
PIPR
10/29/18
NO CHANGE
Target $73
PIPR
Overweight
Glaukos remains 'compelling' name that should be owned, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says feedback on Glaukos' (GKOS) iStent and Inject was again positive at this weekend's American Academy of Ophthalmology meeting. The products are "proving very safe and efficacious," O'Brien tells investors in a research note. Further, the analyst says he has not heard much, if any, commentary on a procedural slowdown of other microinvasive glaucoma surgery cases following the withdrawal of Novartis' (NVS) CyPass, which he believes should be a positive for Glaukos. O'Brien continues to view Glaukos as a "compelling med tech name that should be owned here." He keeps an Overweight rating on the shares with a $73 price target.
DBVT DBV Technologies
$16.70

0.31 (1.89%)

04/05/18
PIPR
04/05/18
NO CHANGE
Target $62
PIPR
Overweight
Piper reiterates Overweight on Aimmune after call with allergist
Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $62 price target after speaking to a community-based allergist whose practice he feels is representative of the U.S. peanut allergy market. The analyst heard three key takeaways that reinforce his thesis for Aimmune's AR101 market potential: Both safety/tolerability are better than expected and completely feasible in most of his patients, several patient segments will likely prefer AR101 in his practice, and there is likely very high demand for any immunotherapy with community doctors likely to use both AR101 and DBV Technologies' (DBVT) Viaskin, if both are approved.
04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
08/20/18
JMPS
08/20/18
NO CHANGE
Target $30
JMPS
Outperform
DBV Viaskin Peanut BLA acceptance could be derisking event, says JMP Securities
After hosting meetings with Kevin Trapp, DBV Technologies' newly appointed Chief Commercial Officer, JMP Securities analyst Liisa Bayko noted the company is prepared to submit its BLA for Viaskin Peanut in October and she looks for acceptance 60 days later, which she said would be the first positive milestone for the company and could be a "meaningful derisking event." Viaskin Peanut is eligible for priority review and her expectation is that DBV will receive it, added Bayko, who reiterated her Outperform rating and $30 price target on the shares.
09/13/18
STFL
09/13/18
INITIATION
Target $35
STFL
Buy
DBV Technologies initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated DBV Technologies with a Buy rating and a price target of $35, saying the stock offers a "favorable" risk-reward over the next 12 months. Archila acknowledges investors' skepticism due to the Viaskin peanut missing its Phase 3 lower confidence level, but adds that his talks with regulatory experts suggest an over 50% probability that the Viaskin Biologic License Application will be accepted and yield an eventual approval.
REGN Regeneron
$345.10

3.56 (1.04%)

11/06/18
PIPR
11/06/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron operational performance, diversifying pipeline on display in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and $450 price target on Regeneron's shares following Q3 top- and bottom-line beats. The analyst notes that over the last five quarters including Q3, EPS has beaten consensus on average by 55c, consistently driven by top-line beats. Combining strong operational performance with continued pipeline maturation and commercial momentum, the analyst continues to like the setup and remains a buyer.
11/14/18
PIPR
11/14/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron survey 'hints at' plateauing dermatitis trends, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says a survey done by his firm's partners at Spherix Global Insights of 102 dermatologists "hints at" plateauing atopic dermatitis use trends for Regeneron Pharmaceuticals' Dupixent. The average number of patients per Dupixent prescriber was up just 0.2 quarter-over-quarter to 15.7, despite prior survey feedback showing projected patients per prescriber up by 8.6 patients, Ramymond tells investors in a research note. However, the analyst points out that this is just "one data point in yet another otherwise very positive survey that continues to indicate significantly increasing use projections." Further, script trends would seem to indicate that strong uptake continues unabated, says Raymond. He views the survey feedback as something worth monitoring, but feels it is not thesis changing, especially with asthma uptake happening now and adolescent atopic dermatitis labeling a "significant" tailwind in the first half of 2019. He keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.
SHPG Shire
$175.59

-3.39 (-1.89%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
11/06/18
RHCO
11/06/18
NO CHANGE
Target $190
RHCO
Buy
Shire price target lowered to $190 from $205 at SunTrust
SunTrust analyst John Boris lowered his price target on Shire (SHPG) to $190 to reflect the impact of the USD appreciation against GBP while also lowering his FY18 EPS view to $15.11 from $15.18. The analyst notes that the investment focus for Shire falls on the November 20th vote by E.U. regulators on its merger with Takeda (TKPYY), adding that the company is on track to secure that approval and for shareholders to vote on the deal in January of next year.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
TEVA Teva
$22.25

-0.37 (-1.64%)

11/06/18
WELS
11/06/18
UPGRADE
Target $40
WELS
Outperform
Wells upgrades Mylan to Outperform, sees more upside after today's rally
Wells Fargo analyst David Maris upgraded Mylan (MYL) to Outperform from Market Perform with an unchanged price target of $40. The stock in afternoon trading is up 18%, or $5.76, to $37.13. Mylan shares have underperformed the S&P 500 Index for the year-to-date, one year, two year, and five year periods and the shares trade at a discount to peer Teva (TEVA), Maris tells investors in a research note titled "Concerns Abound, but Valuation Attractive." The analyst, however, believes Mylan is positioned for near-term outperformance after the company maintained its 2018 earnings guidance. Maris previously saw risk to second half of 2018 estimates, but with today's Q3 results, he now believes the risk to the downside to Q4 estimates is lower than previously thought. Further, Mylan's statement that Q4 guidance can be achieved with or without new approvals "provides some upside to sentiment" if generic Advair or other approvals materialize, says the analyst. Maris thinks that even with today's rally, Mylan shares still have more than 10% additional upside potential to reach fair value.
11/14/18
JEFF
11/14/18
NO CHANGE
Target $21
JEFF
Hold
Teva management sees bottom of generic pricing cycle, says Jefferies
Teva believes that we are approaching the bottom of the generic drug pricing cycle, Jefferies analyst David Steinberg tells investors in a research note after meeting with the company's CEO and CFO in Israel. Management sees a flattening price erosion curve and does not expect that there will be further consolidation amongst buying consortiums, says the analyst. He adds that while the U.S. market will likely show little to no growth, Teva is focusing on international markets. Management believes long-term trends will allow single digit annual revenue growth for the next 20 years, writes Steinberg after the meeting. Further, the analyst points out Copaxone continues to erode at a slower rate than most observers expected and that Teva expects this to continue. He keeps a Hold rating on Teva shares with a $21 price target.
11/05/18
MSCO
11/05/18
UPGRADE
MSCO
Overweight
Teva upgraded to Overweight from Equal Weight at Morgan Stanley
11/05/18
11/05/18
UPGRADE
Target $27

Overweight
Teva upgraded to Overweight on turnaround potential at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Teva to Overweight from Equal Weight, citing three main reasons. First, he expects strong cost cutting to drive earnings that top consensus forecasts. Second, he believes new products should deliver sales that top consensus forecasts. Third, he believes the market will assign Teva shares a higher multiple as the company executes and drives net debt /EBITDA down. Risinger, who noted that his adjusted EBITDA estimates for 2019-2020 are 6%-8% above consensus, raised his price target on Teva shares to $27 from $20.
SNY Sanofi
$45.11

0.56 (1.26%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
11/01/18
LEHM
11/01/18
UPGRADE
LEHM
Equal Weight
Sanofi upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Sanofi to Equal Weight and raised his price target for the shares to EUR 80 from EUR 68 following the company's Q3 results. The analyst sees a more balanced risk/reward profile at current share levels.
11/01/18
11/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nutrisystem (NTRI) upgraded to Outperform from Market Perform at Barrington and to Neutral from Underperform at DA Davidson. 2. SeaWorld (SEAS) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brett Andress saying de-risked expectations following the Q3 pre-announcement create an attractive entry point, as he sees further upside to shares, with his confidence in the company's turnaround bolstered by additional evidence of both a brand and business in recovery mode. 3. Sanofi (SNY) upgraded to Equal Weight from Underweight at Barclays with analyst Emmanuel Papadakis saying he sees a more balanced risk/reward profile at current share levels. 4. Asur (ASR) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla citing valuation. 5. Wex (WEX) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GSK GlaxoSmithKline
$40.35

-0.06 (-0.15%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
GlaxoSmithKline reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated GlaxoSmithKline with a Peer Perform.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
AZN AstraZeneca
$40.67

-0.685 (-1.66%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
AstraZeneca reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated AstraZeneca with an Outperform.
11/13/18
NEED
11/13/18
INITIATION
Target $18
NEED
Buy
PhaseBio initiated with a Buy at Needham
Needham analyst Chad Messer initiated PhaseBio (PHAS) with a Buy rating and a price target of $18, saying it poses an "attractive investment with a near term commercial opportunity from PB2452" - the closes to market threat to AstraZeneca's (AZN) Brilinta to treat orphan cardiopulmonary diseases. The analyst notes that the company is also evaluating PB1046, which is a "weekly injectable form of vasoactive intestinal peptide with a vastly increased half life over the natural form", for potential treatment of rare pulmonary arterial hypertension.
10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
CHD Church & Dwight
$65.42

-0.39 (-0.59%)

10/29/18
JEFF
10/29/18
NO CHANGE
Target $68
JEFF
Buy
Church & Dwight has 'long runway' in U.S. laundry, says Jefferies
Jefferies analyst Kevin Grundy says his U.S. laundry analysis suggests a "long runway" for Church & Dwight. Henkel's premiumization strategy in U.S. laundry creates opportunity for Church & Dwight, Grundy tells investors in a research note. The analyst expects the Church to report "solid" Q3 results and he views the stock's valuation as attractive at current levels. He raised his price target for the shares to $68 from $65 and says the stock remains a core holding with a Buy rating.
11/08/18
OPCO
11/08/18
NO CHANGE
Target $73
OPCO
Outperform
Church & Dwight price target raised to $73 from $66 at Oppenheimer
Oppenheimer analyst Rupesh Parikh raised his price target for Church & Dwight to $73 from $66 after meeting with management and coming away still confident in the company's ability to deliver on evergreen targets and execute on the M&A front. The analyst reiterates an Outperform rating on the shares.
10/10/18
10/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Vipshop (VIPS) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao saying as the "tough competitive environment and harder-than-expected synergy generation," Vipshop is likely to adjust its strategy to re-focus on core off-season apparel distribution and prioritize profitability over sales growth. 2. International Paper (IP) downgraded to Neutral from Buy at Goldman Sachs while WestRock (WRK) was downgraded to Buy from Conviction Buy. 3. Clorox (CLX), Church & Dwight (CHD), and Kimberly-Clark (KMB) were downgraded to Sell from Hold at Deutsche Bank. 4. Sherwin-Williams (SHW) downgraded to Neutral from Buy at Citi with analyst P.J. Juvekar saying "tough" market comments from companies like H.B. Fuller (FUL), PPG (PPG) and RPM (RPL) suggest that coatings companies are likely to be challenged by rising raw materials costs and slowing growth in key end markets, including China. 5. KKR (KKR) downgraded to Neutral from Buy at BofA/Merrill with analyst Michael Carrier citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/18
10/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MCDONALD'S UPGRADED TO BUY: Guggenheim analyst Matthew DiFrisco upgraded McDonald's (MCD) to Buy from Neutral with a $200 price target as he believes the shares valuation discount to large cap peers has widened to an "unjustifiable" level given his outlook for stable to improving same-store sales and greater free cash flow generation. DEUTSCHE CUTS CONSUMER STAPLES STOCKS TO SELL: Deutsche Bank analyst Steve Powers downgraded Clorox (CLX), Church & Dwight (CHD) and Kimberly-Clark (KMB) to Sell from Hold and lowered his price targets to $123, $51, and $99, respectively. While investor appetite for defensive names remains elevated, the fundamental challenges facing Consumer Packaged Goods companies are "somewhat underappreciated," Powers believes. The analyst believes currency and emerging market volatility will pressure numbers in the near-term, while structural competitive and retail pressures will challenge momentum longer-term. PIPER STARTS MICRON AT NEUTRAL: Piper Jaffray analyst Harsh Kumar initiated coverage of Micron Technology (MU) with a Neutral rating and $48 price target. The analyst awaits more clarity surrounding the mid-term dynamics of the memory cycle before getting more constructive on the shares. The memory market as a whole has experienced favorable trends over the last few years, Kumar said. However, given the cyclical nature of the memory market, the analyst prefers to remain on the sidelines until he has a better grasp of the cycle. JPMORGAN ADDS DROPBOX TO FOCUS LIST: JPMorgan analyst Mark Murphy added Dropbox (DBX) to his firm's Analyst Focus List while keeping an Overweight rating on the shares with a $35 price target. While not convinced the "seven-day-old growth tech selloff is over," the analyst sees an improving risk/reward on Dropbox shares and potential for 30%-50% outperformance. He believes investors are "underestimating the stability and consistency of the Dropbox engine," and are overlooking the launch and adoption of its Premium plans. JPMORGAN SAYS GE TURBINE ISSUES MAY BE WORSE THAN THOUGHT: Recently published feedback from a General Electric (GE) H-frame user group event suggests more serious technology issues with the new flagship product, JPMorgan analyst Stephen Tusa said. While most of the focus has been on the technology around the blades, the event indicates a "myriad of shortfalls in other parts of the turbine that we find hard not to consider 'technology flaws,'" Tusa said. Tusa kept an Underweight rating on shares of General Electric.
BSX Boston Scientific
$37.22

0.75 (2.06%)

10/24/18
PIPR
10/24/18
NO CHANGE
Target $40
PIPR
Overweight
Piper continues to recommend purchase of Boston Scientific after earnings
Piper Jaffray analyst Matt O'Brien says that while currency proved more of a drag than expected in Boston Scientific's Q3, the company's outlook remains "strong." There were a couple areas of modest weakness in the quarter, but the key growth drivers, namely Neuromod, MedSurg and Structural Heart, were "quite strong again," O'Brien tells investors in a post-earnings research note. The analyst believes Boston Scientific's market opportunities, along with new products, "will continue to buoy revenue results" in 2019 and 2020. He encourages investors to start or build positions in the name and keeps an Overweight rating on Boston Scientific with a $40 price target.
10/25/18
PIPR
10/25/18
NO CHANGE
Target $25
PIPR
Overweight
Nuvectra recent selloff brings 'excellent entry point,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes the recent Q3 results of neuromodulation incumbents, Boston Scientific (BSX) and Abbott (ABT), "reinforce the dynamic characteristics" of the spinal cord stimulation marketplace. Nuvectra's (NVTR) Algovita is likely one of the beneficiaries and could post upside in the quarter, O'Brien tells investors in a research note. The analyst says Nuvectra continues to be his top-microcap pick with a "reasonable valuation." Further, the recent softness in the shares "provides an excellent entry point for a name that is still in the early innings of gaining SCS share." He keeps an Overweight rating on Nuvectra with a $25 price target.
11/15/18
GUGG
11/15/18
NO CHANGE
Target $45
GUGG
Buy
Boston Scientific price target raised to $45 from $43 at Guggenheim
Guggenheim analyst Chris Pasquale raised his price target on Boston Scientific to $45 and kept his Buy rating, saying its recent acquisitions of 8 private companies for $1.5B has positioned the company for a "best-in-class" topline growth of over 10% in 2020. The analyst notes that the revenue impact of the acquisitions adds to his bullish thesis outlined in July when he added the stock to his Best Ideas list based on his expectation of Lotus coming to market and its non-TAVR pipeline being "underappreciated" by the Street.
10/25/18
ADAM
10/25/18
NO CHANGE
Target $42
ADAM
Buy
Boston Scientific entering 2019 with best fundamentals ever, says Canaccord
Canaccord analyst Jason Mills noted Boston Scientific reported solid Q3 results and said there was nothing in the report to imply a loss of momentum. The analyst believes the company will enter 2019 with its best fundamentals in its history and is very well positioned to deliver organic revenue growth above its peers. Mills reiterated his Buy rating and raised his price target to $42 from $40 on Boston Scientific shares.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/15/18
12/15
04:55
12/15/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

  • 12

    Dec

  • 12

    Dec

TEVA

Teva

$18.46

-0.56 (-2.94%)

18:34
12/14/18
12/14
18:34
12/14/18
18:34
Hot Stocks
Teva, Celltrion announce FDA approval of HERZUMA »

Celltrion and Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVG

Pretium Resources

$7.43

(0.00%)

18:11
12/14/18
12/14
18:11
12/14/18
18:11
Hot Stocks
Pretium Resources: Brucejack approved for production hike to 3,800 tonnes/day »

Pretium Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

17:52
12/14/18
12/14
17:52
12/14/18
17:52
Periodicals
FCA says four U.S. plants to have down-time in January, Detroit News says »

Fiat Chrysler said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

, CCNI

Command Center

$4.00

-0.075 (-1.84%)

17:43
12/14/18
12/14
17:43
12/14/18
17:43
Hot Stocks
Sonoma Pharmaceuticals CEO Jim Schutz resigns, Frederick Sandford succeeds »

Sonoma Pharmaceuticals…

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

CCNI

Command Center

$4.00

-0.075 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

, XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

17:38
12/14/18
12/14
17:38
12/14/18
17:38
General news
Week ending ETF scorecard: Energy, Financials lead the decline »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

IYR

DJ US Real Estate Index Fund

$80.37

-0.14 (-0.17%)

XLP

Consumer Staples Sector SPDR

$54.51

-0.97 (-1.75%)

XLY

Consumer Discretionary Sector SPDR

$102.33

-1.75 (-1.68%)

XLB

S&P Select Materials SPDR

$51.37

-0.37 (-0.72%)

XLF

Financial Select Sector

$24.25

-0.24 (-0.98%)

XLV

Health Care Select Sector SPDR

$88.99

-3.05 (-3.31%)

XLK

Technology Select Sector SPDR

$64.58

-1.6 (-2.42%)

XLI

Industrial Select Sector SPDR

$67.06

-0.95 (-1.40%)

GLD

SPDR Gold Shares

$117.10

-0.44 (-0.37%)

SLV

iShares Silver Trust

$13.69

-0.175 (-1.26%)

USO

United States Oil Fund

$10.83

-0.38 (-3.39%)

UNG

United States Natural Gas Fund

$30.78

-2.64 (-7.90%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.17

-0.365 (-0.44%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.72

-0.125 (-0.11%)

TLT

iShares 20+ Year Treasury Bond Fund

$118.47

0.38 (0.32%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.57

0.19 (0.19%)

SHY

iShares 1-3 Year Treasury Bond

$83.31

0.055 (0.07%)

IWD

iShares Russell 1000 Value

$116.15

-1.71 (-1.45%)

IWF

iShares Russell 1000 Growth

$135.70

-2.96 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEI

Ecology & Environment

$11.50

0.2 (1.77%)

17:35
12/14/18
12/14
17:35
12/14/18
17:35
Hot Stocks
Ecology & Environment receives Nasdaq noncompliance notice »

On December 13, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$8.96

-0.045 (-0.50%)

17:34
12/14/18
12/14
17:34
12/14/18
17:34
Hot Stocks
Luther Burbank announces systematic share repurchase plan »

Luther Burbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$1.33

0.01 (0.76%)

17:31
12/14/18
12/14
17:31
12/14/18
17:31
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLGT

Radiant Logistics

$4.76

-0.06 (-1.24%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on Radiant Logistics »

Radiant Logistics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$22.62

-1.39 (-5.79%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on KalVista »

KalVista files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

17:25
12/14/18
12/14
17:25
12/14/18
17:25
Hot Stocks
POTUS names Mick Mulvaney acting WH chief of staff »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$169.87

-2.585 (-1.50%)

17:20
12/14/18
12/14
17:20
12/14/18
17:20
Hot Stocks
Raytheon awarded $149.44M Navy contract for Standard Missile-2 Block IIIC »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$100.08

-2.73 (-2.66%)

17:15
12/14/18
12/14
17:15
12/14/18
17:15
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNCB

First National Community Bancorp, Inc.

$9.35

0.04 (0.43%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
First National Community Bancorp names R. Gregory Collins as new EVP »

FNCB Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.49

-0.48 (-0.96%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Textron awarded $314.29M Navy contract modification for LLTM procurement »

Textron has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Breaking Hot Stocks news story on Fluidigm »

Levin Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WTFC

Wintrust Financial

$67.41

-0.88 (-1.29%)

17:06
12/14/18
12/14
17:06
12/14/18
17:06
Hot Stocks
Wintrust Financial acquires Elektra Holding in roughly $51.9M deal »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$14.51

-0.35 (-2.36%)

17:04
12/14/18
12/14
17:04
12/14/18
17:04
Syndicate
Breaking Syndicate news story on AMC Entertainment »

AMC Entertainment files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.19

0.07 (0.07%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Equifax Canada acquires JLR Inc. »

Equifax Canada announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

DFS

Discover

$61.83

-1.41 (-2.23%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Discover executive chairman Nelms to step down effective December 31 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTO

AutoWeb

$2.34

-0.01 (-0.43%)

17:00
12/14/18
12/14
17:00
12/14/18
17:00
Hot Stocks
Daniel M. Negari reports 7.1% stake in AutoWeb »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.33

-1.39 (-1.77%)

16:46
12/14/18
12/14
16:46
12/14/18
16:46
Hot Stocks
Canadian National, Unifor Local 100 reach tentative agreement »

CN announced that a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.80

-1.66 (-3.50%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Recommendations
Cisco analyst commentary at Tigress Financial »

Tigress Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 10

    Jan

  • 04

    Mar

TEL

TE Connectivity

$73.01

-0.59 (-0.80%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Hot Stocks
TE Connectivity raises quarterly dividend to 46c from 44c per share »

TE Connectivity board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.